In this CE activity, expert faculty assess the latest data from gene therapy and tyrosine kinase inhibitor trials. They also review the FDA’s latest guidance for the design of clinical trials as well as the newest data regarding advances in vitreoretinal care.
- Provider:Vindico Medical Education, LLC
- Activity Link: https://www.healio.com/cme/ophthalmology/20241210/3-the-retina-radar-with-dr-arshad-khanani/overview
- Start Date: 2024-12-31 06:00:00
- End Date: 2024-12-31 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.5 hours
- Commercial Support: Source: AbbVie Inc. - Amount: 2500.0 - Is Kind Support: False Source: Alimera Sciences, Inc. - Amount: 625.0 - Is Kind Support: False Source: Apellis Pharmaceuticals, Inc. - Amount: 937.5 - Is Kind Support: False Source: Astellas - Amount: 1562.5 - Is Kind Support: False Source: EyePoint Pharmaceuticals, Inc. - Amount: 625.0 - Is Kind Support: False Source: Genentech, a member of the Roche Group - Amount: 4062.5 - Is Kind Support: False Source: Neurotech Pharmaceuticals, Inc. - Amount: 625.0 - Is Kind Support: False Source: Ocular Therapeutix, Inc. - Amount: 618.75 - Is Kind Support: False Source: Opthea - Amount: 937.5 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc. - Amount: 4687.5 - Is Kind Support: False Source: REGENXBIO Inc. - Amount: 625.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest